electroCore, Inc. (ECOR) News
Filter ECOR News Items
ECOR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ECOR News Highlights
- For ECOR, its 30 day story count is now at 3.
- Over the past 21 days, the trend for ECOR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest ECOR News From Around the Web
Below are the latest news stories about electroCore Inc that investors may wish to consider to help them evaluate ECOR as an investment opportunity.
ECOR: Different Strokes for Different FolksBy John Vandermosten, CFA NASDAQ:ECOR READ THE FULL ECOR RESEARCH REPORT Since Our Last Update Since our last update , electroCore Inc. (NASDAQ:ECOR) has provided several updates including a 2021 Shareholder Letter, completion of enrollment of its TRANSIT study in post-operative ileus, and three abstracts presented at the International Stroke Conference with promising early data. Highlights since |
Data Presented at 2022 International Stroke Congress Suggests Role for Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute StrokeClinical Trial (n=69) suggests safety and feasibility of nVNS for the acute treatment of stroke. Relative Ischemic Lesion Growth Decreased by 65.9% with nVNS vs. Sham Treatment. ROCKAWAY, N.J., Feb. 09, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced top line data from three abstracts being presented at the American Heart Associations’ 2022 International Stroke Conference (February 9-11, 2022, New Orleans) on the possi |
electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative IleusData on 97-patient, randomized, sham-controlled study to be presented at medical congress later this yearROCKAWAY, N.J., Feb. 01, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced enrollment has been completed for the TRANSIT study of non-invasive vagal nerve stimulation (nVNS) to reduce ileus after colorectal surgery. This randomized, participant blinded, sham-controlled study is being sponsored by the United Kingdom’s |
electroCore, Inc. Announces Three Abstracts to be Presented at International Stroke Conference 2022Clinical Research Conducted on Non-invasive Vagus Nerve Stimulation (nVNS) for the Acute Treatment of StrokeROCKAWAY, N.J., Jan. 25, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced three abstracts focusing on the possible mechanistic or clinical role of nVNS for the acute treatment of stroke will be presented at the American Heart Association’s 2022 International Stroke Conference, February 9th – 11th, 2022, in New Orl |
Neurostimulation Devices Market revenue to cross USD 13.6 Bn by 2027: Global Market Insights Inc.Major neurostimulation devices market players include Abbott, Boston Scientific, IntraPace, Laborie, LivaNova, Medtronic, Neuronetics, SPR Therapeutics, Cyberonics, ElectroCore Inc., Aleva Neurotherapeutics SA, Synapse Biomedical Inc., MicroTransponder, RS Medical, Helbling holding Ag, EndoStim Inc., and BioControl Medical. SELBYVILLE, Del. , Jan. 20, 2022 /PRNewswire/ -- The neurostimulation devices market size is anticipated to record a valuation of USD 13.6 billion by 2027, according to the most recent study by Global Market Insights Inc. Increasing adoption and introduction of advanced neurostimulation devices will drive the overall market growth. Increasing demand for minimally invasive surgeries in developed countries attributed to the rising preference among patients for shorter ... |
H.C. Wainwright Thinks Electrocore’s Stock is Going to RecoverE…. |
electroCore anticipates FY21 revenue to be above consensuselectroCore (ECOR) anticipates FY21 revenue to be ~$5.5M (consensus $5.3M), +55% Y/Y.100 VA and DoD military treatment facilities have purchased gammaCore products through December |
electroCore Announces Shareholder Letter and Full-Year 2021 Business UpdateCompany anticipates full-year 2021 revenue of approximately $5.5 million, an approximately 55% increase over full-year 2020ROCKAWAY, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) today published a letter from the company’s Board of Directors to shareholders. The letter is included in its entirety, below: Dear Shareholders: We continue to be excited about the long-term prospects of our Company and would like to share some of the reasons for our optimism. We are investin |
ECOR: New Distribution Agreements Complement E-Commerce InitiativeBy John Vandermosten, CFA NASDAQ:ECOR READ THE FULL ECOR RESEARCH REPORT Since Our Last Update Since our last report , electroCore Inc. (NASDAQ:ECOR) has provided several updates including announcement of a new patent, publications, multiple new distribution agreements, Breakthrough Device Designation for nVNS 1 in PTSD 2 , and the launch of US and UK ecommerce stores. Highlights since our last |
ElectroCore''s Vagus Nerve Stimulator Wins Breakthrough Device Tag For Stress DisorderThe FDA has granted Breakthrough Designation to ElectroCore Inc''s (NASDAQ: ECOR ) gammaCore nVNS device for posttraumatic stress disorder (PTSD). The device showed a reduction of symptoms of Full story available on Benzinga.com |